Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1- piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 421-428

  Han, Feng ^a   Lu, Ying Mei ^b   Hasegawa, Hideyuki ^b   Kanai, Hiroshi ^b   Hachimura, Erika ^b   Shirasaki, Yasufumi ^c   Fukunaga, Kohji ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b TOHOKU UNIVERSITY   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [4 (3 CHLORO 2 METHYLPHENYL) 1 PIPERAZINYL]ETHYL] 5,6 DIMETHOXY 1 (4 IMIDAZOLYLMETHYL) 1H INDAZOLE DIHYDROCHLORIDE 3.5 HYDRATE; ATRIAL NATRIURETIC FACTOR; CALMODULIN INHIBITOR; CALPAIN; CAVEOLIN 3; DY 9760E; DYSTROPHIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN TYROSINE KINASE; SPECTRIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CELL MEMBRANE; CELL PROTECTION; CONTROLLED STUDY; DISSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MOUSE; NITRATION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; UPREGULATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENTS; CAVEOLIN 3; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTROPHIN; GLYCOPROTEINS; HEART; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; INDAZOLES; MALE; MICE; MICE, INBRED STRAINS; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; SPECTRIN;

EID: 76749160244     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.161646     Document Type: Article

References (34)

1. Armstrong SC, Latham CA, Shivell CL, and Ganote CE (2001) Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol 33:1165-1179.
2. Brown DW, Giles WH, and Croft JB (2000) Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 140:848-856.
3. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, and Michel T (1996) Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem271:22810-22814.
4. García-Cardeña G, Oh P, Liu J, Schnitzer JE, and Sessa WC (1996) Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A 93:6448-6453.
5. Haider AW, Larson MG, Benjamin EJ, and Levy D (1998) Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32:1454-1459.
6. Han F, Shirasaki Y, and Fukunaga K (2006) Microsphere embolism-induced endothelial nitric oxide synthase expression mediates disruption of the blood-brain barrier in rat brain. J Neurochem 99:97-106.
7. Harris AS, Croall DE, and Morrow JS (1989) Calmodulin regulates fodrin susceptibility to cleavage by calcium-dependent protease I. J Biol Chem 264:17401-17408.
8. Hashiguchi A, Yano S, Morioka M, Hamada J, Shirasaki Y, Kochi M, and Fukunaga K (2004) The post-ischemic administration of 3-[2-[4-(3-chloro-2- methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl) -1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, prevents delayed neuronal death in gerbil hippocampus. J Pharmacol Sci 96:65-72.
9. Hashimoto M, Takada Y, Takeuchi Y, Kasahara J, Hisa H, Shirasaki Y, and Fukunaga K (2005) Cytoprotective effect of 3-[2-[4-(3-chloro-2-methylphenyl)-1- piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) against ischemia/reperfusion-induced injury in rat heart involves inhibition of fodrin breakdown and protein tyrosine nitration. J Pharmacol Sci 98:142-150.
10. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, and Litwin SE (2003) Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 285:H1261-H1269.
11. Inserte J, Garcia-Dorado D, Hernando V, and Soler-Soler J (2005) Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circ Res 97:465-473.
12. Jugdutt BI (2003) Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 3:1-30.
13. Katori T, Donzelli S, Tocchetti CG, Miranda KM, Cormaci G, Thomas DD, Ketner EA, Lee MJ, Mancardi D, Wink DA, et al. (2006) Peroxynitrite and myocardial contractility: in vivo versus in vitro effects. Free Radic Biol Med 41:1606-1618.
14. Kawada T, Masui F, Kumagai H, Koshimizu M, Nakazawa M, and Toyo-Oka T (2005) A novel paradigm for therapeutic basis of advanced heart failure - assessment by gene therapy. Pharmacol Ther 107:31-43.
15. Kohr MJ, Wang H, Wheeler DG, Velayutham M, Zweier JL, and Ziolo MT (2008) Biphasic effect of SIN-1 is reliant upon cardiomyocyte contractile state. Free Radic Biol Med 45:73-80.
16. Levy D, Larson MG, Vasan RS, Kannel WB, and Ho KK (1996) The progression from hypertension to congestive heart failure. Jama 275:1557-1562.
17. Letavernier E, Perez J, Bellocq A, Mesnard L, de Castro Keller A, Haymann JP, and Baud L (2008) Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 102:720-728.
18. Loufrani L, Dubroca C, You D, Li Z, Levy B, Paulin D, and Henrion D (2004) Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler Thromb Vasc Biol 24:671-676.
19. Lu YM, Han F, Shioda N, Moriguchi S, Shirasaki Y, Qin ZH, and Fukunaga K (2009a) Phenylephrine-induced cardiomyocyte injury is triggered by superoxide generation through uncoupled endothelial nitric-oxide synthase and ameliorated by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxyindazole (DY-9836), a novel calmodulin antagonist. Mol Pharmacol 75:101-112.
20. Lu YM, Shioda N, Han F, Kamata A, Shirasaki Y, Qin ZH, and Fukunaga K (2009b) DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities. Cardiovasc Ther 27:17-27.
21. Lu YM, Shioda N, Han F, Moriguchi S, Kasahara J, Shirasaki Y, Qin ZH, and Fukunaga K (2007) Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes. Biochem Pharmacol 74:1727-1737.
22. Matsumura Y, Saeki E, Inoue M, Hori M, Kamada T, and Kusuoka H (1996) Inhomogeneous disappearance of myofilament-related cytoskeletal proteins in stunned myocardium of guinea pig. Circ Res 79:447-454.
23. Meijs MF, de Windt LJ, de Jonge N, Cramer MJ, Bots ML, Mali WP, and Doevendans PA (2007) Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 14:157-171.
24. Michel T and Feron O (1997) Nitric oxide synthases: which, where, how, and why? J Clin Invest 100:2146-2152.
25. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K, Halushka MK, et al. (2008) Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117:2626-2636.
26. Rotter B, Kroviarski Y, Nicolas G, Dhermy D, and Lecomte MC (2004) AlphaII-spectrin is an in vitro target for caspase-2, and its cleavage is regulated by calmodulin binding. Biochem J 378:161-168.
27. Saido TC, Sorimachi H, and Suzuki K (1994) Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 8:814-822.
28. Seubert P, Baudry M, Dudek S, and Lynch G (1987) Calmodulin stimulates the degradation of brain spectrin by calpain. Synapse 1:20-24.
29. Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87:1285-1342.
30. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, et al. (2005) Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115:1221-1231.
31. Toyo-Oka T, Kawada T, Nakata J, Xie H, Urabe M, Masui F, Ebisawa T, Tezuka A, Iwasawa K, Nakajima T, et al. (2004) Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. Proc Natl Acad Sci U S A 101:7381-7385.
32. Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13:1637-1652.
33. Yoshida H, Takahashi M, Koshimizu M, Tanonaka K, Oikawa R, Toyo-oka T, and Takeo S (2003) Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction. Cardiovasc Res 59:419-427.
34. Yoshida K, Inui M, Harada K, Saido TC, Sorimachi Y, Ishihara T, Kawashima S, and Sobue K (1995) Reperfusion of rat heart after brief ischemia induces proteolysis of calspectin (nonerythroid spectrin or fodrin) by calpain. Circ Res 77:603-610.